Paediatric Acute Leukaemia Translocations (Accredited)

 

The WHO classification of haematopoietic tumours uses genetic markers to aid in the classification of Precursor Lymphoid Neoplasms. The identification of the t(12;21) (TEL-AML1 or ETV6-RUNX1), t(4;11) (KMT2A-AFF1 or MLL-AF4) and t(1;19) (E2A-PBX1 or TCF3-PBX1) are useful diagnostic tools and also have prognostic significance that allow for therapeutic stratification.

 

In this programme participants are provided with lyophilised cell-lines for t(12;21) (TEL-AML1 or ETV6-RUNX1), t(4;11) (KMT2A-AFF1 or MLL-AF4) and t(1;19) (E2A-PBX1 or TCF3-PBX1) analysis. Participants are asked to submit qualitative results, together with details of the methodology. All samples mimic diagnostic specimens and are therefore not suitable for MRD analysis; this may be subject to change dependent on participants’ feedback. Instructions for storage, reconstitution and use of the lyophilised samples are included with the samples. Three send-outs are issued per annum, with each send-out consisting of two samples.

 

Pre issue testing of samples for this programme is subcontracted, although the final decision about sample suitability lies with the EQA provider; no other activities in relation to this EQA programme are subcontracted.

 

To register for this programme, please click here.

Example Paediatric Acute Leukaemia Translocations Report
Example PALT Report.pdf
Adobe Acrobat document [741.1 KB]
Paediatric Acute Leukaemia Translocations Performance Monitoring System
PALT Performance Monitoring System.pdf
Adobe Acrobat document [194.8 KB]
Print Print | Sitemap

Follow Us Online!
Facebook Twitter LinkedIn Youtube

Disclaimer

Last updated 04/09/19 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information, please click here.


Please click here for our privacy policy.


The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).